SLU-PP-332
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
SLU-PP-332 is a synthetic small molecule developed as an agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), a family of nuclear receptors that help regulate cellular metabolism. It is frequently described as an “exercise mimetic” because it is studied for its ability to switch on some of the same metabolic programs that endurance exercise activates.
Unlike many compounds in this category, SLU-PP-332 is not a peptide — it is a small-molecule research chemical. It emerged from academic drug-discovery work and is primarily used as a chemical probe for studying ERR signaling.
The evidence base is preclinical. Reported effects come almost entirely from cell-culture and mouse studies, and human clinical data is very limited. It is not approved by any major regulator for therapeutic use.
How it works
Estrogen-related receptors sit upstream of genes involved in mitochondrial biogenesis, fatty-acid oxidation, and cellular respiration — the aerobic energy machinery that endurance training also engages. By activating these receptors, SLU-PP-332 has been reported in preclinical models to increase mitochondrial density and energy expenditure without the animal actually exercising.
In mouse studies it has been associated with an acute “aerobic exercise” gene-expression response in skeletal muscle and with increased fat oxidation. The relevance of these mechanisms to humans has not been established.
Reported benefits
- Increased mitochondrial density and cellular energy expenditure (preclinical data)
- Enhanced fatty-acid oxidation and reduced fat-mass accumulation in animal models
- Improved exercise endurance and insulin sensitivity in mouse studies
These are reported findings from preclinical research, not guaranteed outcomes in humans.
Considerations & side effects
Because SLU-PP-332 is a preclinical compound with essentially no published human safety data, its side-effect profile and long-term risks in people are not characterized. Any discussion of tolerability is extrapolated from animal work rather than controlled human trials.
Purity and identity vary widely in the research-chemical market, and mislabeled or contaminated material is a real concern. SLU-PP-332 is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is SLU-PP-332?
A synthetic small-molecule agonist of the estrogen-related receptors (ERRα, β, and γ), developed as a research tool and often described as an exercise mimetic because it activates some of the same metabolic pathways as aerobic exercise.
Is SLU-PP-332 FDA-approved?
No. It is a preclinical compound with no approval from the FDA or any major regulator for human use, and is sold for research purposes only.
Is it a peptide?
No. Despite often being grouped with research peptides, SLU-PP-332 is a synthetic small molecule, not a peptide.
Is there human data?
Human clinical data is very limited. Nearly all of the reported effects come from cell and animal (mouse) studies.
References
- Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ↗
- Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. ↗
- Okda HE, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. ↗
Related compounds
5-Aminoimidazole-4-carboxamide ribonucleotide, an AMPK activator that mimics AMP to enhance metabolic activity and endurance. Preclinical exercise mimetic compound.
Small molecule NNMT enzyme inhibitor. Increases NAD+ levels in fat cells, promoting energy expenditure and reducing fat accumulation without affecting appetite.
Lipotropic injection blend typically containing methionine, inositol, choline, and B12. Supports liver function and promotes fat metabolism.